Valuation : TOUE BIOPAR

Market Cap 1.24B 1.06B 1B 914M 1.71B 117B 1.71B 11.87B 4.59B 59.95B 4.65B 4.55B 191B P/E 2023
-2.95x
P/E 2024 -7.02x
Enterprise Value 980M 843M 793M 723M 1.35B 92.66B 1.36B 9.4B 3.63B 47.45B 3.68B 3.6B 151B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 year 26.31
Extreme 26.309
48.27
3 years 9.18
Extreme 9.18
48.31
5 years 9.18
Extreme 9.18
48.31
10 years 9.18
Extreme 9.18
48.31
Date Insider Type Main position Quantity % Market Cap. Importance
28/10/25 OtherCompany 24,030,382 93.6139%
28/10/25 Tender

General Counsel

252,504 0.9837%
28/10/25 Issuer sale

Chairman

51,800 0.2018%

Financials

2023 2024
Net sales - -
Net income -42.12M -36.23M -34.07M -31.1M -58.17M -3.98B -58.36M -404M -156M -2.04B -158M -155M -6.5B -73.21M -62.96M -59.22M -54.06M -101M -6.92B -101M -702M -271M -3.55B -275M -269M -11.29B
Net Debt -203M -174M -164M -150M -280M -19.15B -281M -1.94B -751M -9.81B -761M -744M -31.24B -258M -222M -209M -191M -356M -24.41B -358M -2.47B -957M -12.5B -969M -948M -39.81B
Logo TOUE BIOPAR
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.
Employees
77
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. TRML Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!